Previous 10 | Next 10 |
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is the focus of IBN's latest stock spotlight. The company's shares have moved 4.3% on the day to $25.49. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 ...
2024-01-08 03:18:45 ET Summary BridgeBio’s FDA filing for acoramidis and advances in KRAS mutation cancer treatment contrast with growing financial losses. Acoramidis competes with Pfizer’s ATTR-CM treatments; BBIO's oncology focus includes promising KRAS inhibitors ...
PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pre...
The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct inhibitor of KRAS G12C that binds to the Switch II pocket in both the ...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2023-12-18 05:34:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq . However, the small-to-mid cap index appears to be closing the gap. After a st...
- BridgeBio has dosed the first child in PROPEL 3, a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial evaluating the efficacy and safety of infigratinib in children with achondroplasia - The U.S. Food and Drug Administration (FDA) and European Union (EU) European Med...
2023-12-12 20:24:54 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased slightly to $24.64B, with 80 holdings. The largest positions in the portfolio are Visa, Workday, Amazon.com, United Parcel Service, and Danaher Corp. New stakes include Block Inc., Freep...
2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares ( HBANL ) +3% . Genmab ( GMAB ) +3% . Losers: Fluence En...
2023-12-05 12:04:02 ET More on BridgeBio Pharma BridgeBio Pharma: Taking Some Profits BridgeBio: Bets Acoramidis As The Pfizer Spoiler BridgeBio draws Buy rating at Cantor citing 100% upside BridgeBio Pharma to issue 9.2M shares through PIPE financing ...
News, Short Squeeze, Breakout and More Instantly...
BridgeBio Pharma Inc. Company Name:
BBIO Stock Symbol:
NYSE Market:
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biop...
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pres...
- In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (p=0.04), with no safety signals of potential clinical concern - Among ATTRibute-CM part...